Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

>

Net loss $(13,445) $(8,863)

Basic and diluted net loss

per share of common stock $(0.18) $(0.13)

Basic and diluted weighted average number

of shares of common stock outstanding 72,726 70,146

MEMORY PHARMACEUTICALS CORP.

CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

March 31, December 31,

2008 2007

ASSETS

Cash, cash equivalents and marketable securities $27,493 $38,201

Other current assets 1,359 1,417

Restricted cash 505 505

Deferred financing costs, net 444 519

Property and equipment, net 5,525 5,868

Total assets $35,326 $46,510

LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY

Current liabilities (excluding deferred revenue) $11,674 $8,789

Equipment notes payable, less current portion 31 66

Loan payable, less current portion 9,669 10,831

Deferred revenue 17,715 18,051

Other non-current liabilities 495 506

Total liabilities 39,584 38,243

Stockholders' (deficit) equity (4,258) 8,267

Total liabilities and

stockholders' (deficit) equity $35,326 $46,510


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... Therapeutics is a privately-held, clinical-stage company developing novel ... Company,s lead product, JVS-100, encodes Stromal cell-Derived Factor ... damaged tissue through recruitment of circulating stem cells ... cell death and restoration of blood flow.  Juventas ...
... Reportlinker.com announces that a new market research ... Analytical Tool - Lymphoma ... Summary "Analytical Tool: Lymphoma" offers ... of strategic possibilities that have emerged in lymphoma ...
... of the American Crystallographic Association (ACA) will be held ... Louisiana. Crystallography is the science devoted to exploring the ... complicated molecules. The study of biomolecules, such as proteins ... often calculated by crystallographers using beams of X-rays sent ...
Cached Biology Technology:Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit 2Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit 3Reportlinker Adds Analytical Tool - Lymphoma 2Reportlinker Adds Analytical Tool - Lymphoma 3Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 2Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 3Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 4
(Date:7/10/2014)... 27, 2014  The American Academy of Forensic ... Standards and Technology (NIST) and the Department of ... and forensic science expert members to the Forensic ... element of the NIST,s Organization of Scientific Area ... first appointments made to the new FSSB that ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
(Date:7/10/2014)... , July 2, 2014  Unisys Corporation,s (NYSE: ... , Unisys Nederland N.V., today announced that it has been ... implement and manage a new Basic Provision Biometrics solution for ... Unisys won the contract with a solution based on ... software. The term of the contract is up to seven ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... locals is a key ingredient in the success of marine ... largest-scale study to date of how coastal communities influence successful ... was a critical factor in whether or not a reserve ... local involvement in research and management. The team looked ...
... memory loss and cognitive decline among older people with diabetes, ... more than 900 men and women aged between 60 and ... the age of 40. They found that brain function ... cortisol. Dr Rebecca Reynolds, of the University of Edinburgh,s ...
... Anyone who grew up in a large family likely remembers hearing ... kids to keep it down, research shows that sleep also is ... world. Rebecca Gomez, Richard Bootzin and Lynn Nadel in the ... babies who are able to get in a little daytime nap ...
Cached Biology News:Participaton 'important for healthy marine parks' 2Babies and sleep: Another reason to love naps 2
Form: Concentrated Applications: ELISA...
Form: Concentrated Applications: ELISA...
ANTI S. GROUP AG:H...
... the Flp-In System creates isogenic cell ... levels of the protein of interest. ... Figure 3. In this experiment the ... was subcloned into pcDNA5/FRT and transfected ...
Biology Products: